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Infections caused by Panton-Valentine leukocidin-positive Staphylococcus aureus (PVL-SA) mostly present as recurrent skin
abscesses and furunculosis. However, life-threatening infections (eg, necrotizing pneumonia, necrotizing fasciitis, and osteomyelitis)
caused by PVL-SA have also been reported.
We assessed the clinical phenotype, frequency, clinical implications (surgery, length of treatment in hospitals/intensive care units,
and antibiotic treatments), and potential preventability of severe PVL-SA infections in children.
Total, 75 children treated for PVL-SA infections in our in- and outpatient units from 2012 to 2017 were included in this retrospective
study.
Ten out of 75 children contracted severe infections (PVL-methicillin resistant S aureus n=4) including necrotizing pneumonia (n=
4), necrotizing fasciitis (n=2), pyomyositis (n=2; including 1 patient who also had pneumonia), mastoiditis with cerebellitis (n=1),
preorbital cellulitis (n=1), and recurrent deep furunculosis in an immunosuppressed patient (n=1). Speciﬁc complications of PVL-SA
infections were venous thrombosis (n=2), sepsis (n=5), respiratory failure (n=5), and acute respiratory distress syndrome (n=3).
The median duration of hospital stay was 14 days (range 5–52 days). In 6 out of 10 patients a history suggestive for PVL-SA
colonization in the patient or close family members before hospital admission was identiﬁed.
PVL-SA causes severe to life-threatening infections requiring lengthy treatments in hospital in a substantial percentage of
symptomatic PVL-SA colonized children. More than 50% of severe infections might be prevented by prompt testing for PVL-SA in
individuals with a history of abscesses or furunculosis, followed by decolonization measures.
Abbreviations: ARDS = acute respiratory distress syndrome, CA-MRSA = community acquired MRSA, DVT = deep venous
thrombosis, ICU = intensive care unit, IMC = intermediate care unit, MRSA = methicillin-resistant Staphylococcus aureus, MSSA =
methicillin sensitive Staphylococcus aureus, PVL = Panton-Valentine leukocidin, PVL-SA = Panton-Valentine leukocidin positive
Staphylococcus aureus, SA = Staphylococcus aureus, SSTI = skin and soft tissue infections, URTI = upper respiratory tract
infection.
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In recent years, the staphylococcal exotoxin Panton-Valentine
leukocidin (PVL) has been recognized for its involvement in
recurrent skin and soft tissue infections (SSTI).[1,2] While PVL-
negative Staphylococcus aureus strains are still the predominant
cause for SSTI, PVL-positive S aureus strains (PVL-SA) are
responsible for a growing number of local epidemic outbreaks
and serious illnesses.[3,4] PVL-SA infections are characterized by
multiple or recurrent furuncles, abscesses, or periorbital
infections.[2,5] Options to prevent recurrent SSTI include a
decolonization protocol comprising mupirocin nasal ointment,
antiseptic throat rinses, antiseptic washings, change of towels, bed
linen, and clothes; and disinfection of potentially contaminated
items over a period of 5 days[6]; see also: www.pvl-abszess.de.
Although PVL-SA is primarily known for causing furunculosis,
it is also associated with life-threatening infections such as
necrotizing pneumonia, necrotizing fasciitis, and osteomyelitis,
especially in young, previously healthy patients.[7,8]
The 2-component pore-forming leucocidin is coded by
bacteriophage genes lukS and lukF and can be expressed by
both methicillin-sensitive (MSSA) and methicillin-resistant
(MRSA) strains of S aureus.[9] The human-pathogen interaction
of PVL-SA remains poorly understood and in vitro studies and
murine models often show conﬂicting results.[10–13] Regional
differences in MRSA and MSSA distribution have been reported.
Most of the PVL-SA strains in Europe have been identiﬁed to be
MSSA,[14] while in the US, the main causes of PVL-SA infections
are a variety of community-acquired MRSA (CA-MRSA) strains,
especially strain USA-300.[15]
In Germany, when S aureus is identiﬁed in culture, assessment
of PVL expression by lukS/lukF using polymerase chain reaction
(PCR) is not performed routinely. Moreover, knowledge of PVL-
SA and its clinical consequences remains insufﬁcient in clinicians
treating the patients with PVL-SA infections, leading to a
signiﬁcant diagnostic delay. Many PVL-SA colonized patients
suffer from recurrent SSTI and may receive multiple antibiotic
treatments and surgeries before diagnosis and decolonization.
Some patients even undergo testing for immunodeﬁciency, before
PVL-SA colonization is considered.[16,17]
The aims of this study were to(1) determine the clinical spectrum and the frequency of severe
infections due to PVL-SA, in children treated at an university
hospital from 2012 to 2017,(2) report the length of treatment in affected children at hospitals/
intensive care units (ICU), and(3) identify the cases in which severe disease and prolonged
hospital stay may have been preventable.2. Methods
We conducted a retrospective case study of children who were
treated in our in- and outpatient units (Charité Universitätsme-
dizin Berlin – Childrens’ Hospital) for PVL-SA infections from
January 2012 to December 2017. Only patients who had been
tested positive for PVL + SA in at least 1 sample (naso-pharyngeal
swabs and/or swabs from other location, eg, tracheobronchial
secretion or material from SSTI) were included in this study.
Swabs were cultivated on Columbia agar with 5% sheep
blood. Species identiﬁcation and antimicrobial susceptibility
testing were performed using a Vitek 2 system, applying EUCAST
breakpoints. The detection of PVL LukS/LukF was performed2using commercially available PCR (eazyplex MRSAplus
REF7611; Amplex Biosystems GmbH, Giessen, Germany).
Molecular genetic testing for PVL was not routinely performed
by our microbiology division after isolation of S aureus but was
requested when the clinical course was suggestive for an infection
with PVL-SA.
Patient records were retrieved from electronic medical records
and archived ﬁles. We deﬁned “severe infection” as “intravenous
antibiotic treatment” and “admission to an ICU” or “admission
to an intermediate care unit (IMC)” or “major emergency
surgery” associated with active PVL-SA infection in contrast to
mere asymptomatic colonization or minor skin infections. In the
identiﬁed cases, we collected data on duration of hospital stay
in days, antibiotic treatment, surgery, as well as ventilation
assistance. Potential prevention options were retrospectively
assessed via telephone interviews. We obtained written informed
consent to publish diagnostic images from the patient’s
custodians.
Data processing and statistical analyses: data were processed
using Microsoft Excel 2013.3. Results
A total of 75 children treated for PVL-SA infection were included
in the analysis. Sixty-ﬁve children suffered from SSTI and/or
hordeola with PVL-SA detection in SSTI material or nasopha-
ryngeal swabs.[5] Ten children presented with infections that
fulﬁlled the criteria of a severe infection. Data about these
patients are presented in Table 1.
Age of the patients ranged from 1 week to 15 years (mean age
5.5 years). Six patients were boys and 4 were girls. Two patients
presented with serious pre-existing conditions: patient 5 with
neonatal drug withdrawal and asymptomatic congenital cyto-
megalovirus infection and patient 9 with status post heart
transplantation and subsequent immunosuppressive treatment.
MRSA was detected in 4 cases. Clinical manifestations included
necrotizing pneumonia (n=4), necrotizing fasciitis (n=2),
pyomyositis (n=2), mastoiditis (n=1), preorbital cellulitis (n=
1), and recurrent deep furunculosis in an immunosuppressed
patient (n=1). Speciﬁc complications of severe PVL-SA infections
were venous thrombosis (n=2), sepsis (n=5), cerebellitis (n=1),
respiratory failure (n=5), and acute respiratory distress
syndrome (ARDS; n=3). The median hospital stay was 14 days
(range 5–52 days) and the median ICU/ IMC stay was 10 days
(range 0–52 days). All patients survived; 1 patient had residual
disability after discharge (patient 6, see below). Primary
immunodeﬁciency (in particular, chronic granulomatous disease)
was excluded in all patients with severe infections.3.1. Necrotizing pneumonia
Four children who had previously been in good general health
were diagnosed with necrotizing pneumonia. Four days before
his admission, patient 1 had an axillary abscess surgically incised
and drained. Patients 3 and 4 had close relatives who had
recurrent SSTI. In 3 patients, pneumonia was preceded by 3 to 10
days of symptoms of upper respiratory tract infections (URTI).
One patient was diagnosed with inﬂuenza A-H5N1 and 1 with
human respiratory-syncytial-virus-B. PVL-SA was cultured from
blood, pleural exudate, sputum, and bronchial lavage samples.
CA-MRSA was detected in 2 patients. Figures 1 and 2 show
initial imaging of patient 4 and 6, respectively. Intensive care
Table 1



















1 Male 172 Necrotizing pneumonia None Axillary abscess None None No Left femoral vein 14 13
Pyomyositis thrombosis
2 Male 9 Necrotizing fasciitis Purulent conjunctivitis None None Yes; unspeciﬁed No None 14 10
3 Male 12 Necrotizing pneumonia None None Yes Yes; unspeciﬁed Yes None 51 29
4 Female 14 Necrotizing pneumonia None None Yes Yes; RSV-B3 No None 18 14
5 Male 0 Necrotizing fasciitis NDW4 Furunculosis None None Yes None 37 37
Congenital CMV5 Panaritium
Purulent conjunctivitis
6 Male 182 Necrotizing pneumonia None None None Yes; Inﬂuenza A Yes None 58 58
7 Male 138 Mastoiditis None Furunculosis Yes None Yes Cerebral sinus 14 14
Cerebellitis vein thrombosis
8 Female 61 Pyomyositis None None None None No None 8 0
9 Female 100 Furunculosis s/p Heart-transplantation Furunculosis None None No None 7 7
Immunosuppression
10 Female 0 Preorbital cellulitis None None None None No None 5 5
Furunculosis
CMV= cytomegalovirus, d=days, ICU= intensive care unit, IMC= intermediate care unit, MRSA=methicillin-resistant Staphylococcus aureus, NDW=neonatal-drug-withdrawal, RSV= respiratory-syncytial-
virus, SSTI= skin and soft tissue infections (before admission), URTI=upper respiratory tract infections (before admission).
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ventilation assistance (including veno-venous extracorporeal
membrane oxygenation, controlled ventilation, noninvasive
ventilation, and heated humidiﬁed high ﬂow therapy), and
therapeutic anticoagulation (see below). Complications observed
included sepsis, ARDS, pyomyositis, and deep vein thrombosis
(DVT). Patients 1, 3, and 4 were discharged in satisfying general
health. After a lengthy rehabilitation due to complications and re-
admission, patient 6 had persisting postintensive care syndrome,
including reduced lung capacity (Fig. 3) and critical illness
polyneuropathy.3.2. Invasive soft tissue infections
Two patients were diagnosed with necrotizing fasciitis of the
thorax. Patient 2, a previously healthy infant, initially presented
with symptoms of URTI and purulent conjunctivitis. Within
hours after admission, he rapidly developed swelling and rednessFigure 1. Patient 4 at admission. Coronal CT of the chest. Lobar pneumonia of
the left lung. Small arrows: border of pleural empyema with gas inclusions
(small black arrows). CT = computed tomography.
3of the right thorax. Patient 5 was an in-patient in the neonatal
ICU receiving treatment for neonatal drug withdrawal from
opioids. Six days after birth, he developed multiple panaritia,
purulent conjunctivitis, and purulent pustules of the left axilla. At
4 weeks, he developed rapid swelling and redness of the left
thorax (Fig. 4). In both patients, early surgical intervention with
necrosectomy and drainage, in combination with broad
antibiotic treatment, led to satisfying improvement of the clinical
situation. Negative pressure wound therapy was used in patient
2. Both patients were discharged in satisfying general health.
Two patients were diagnosed with pyomyositis. Three days
after admission, while still in intensive care, patient 1 (see above)Figure 2. Patient 6 at admission. Anteriorposterior radiograph of the chest at
the time of admission. Left lung: Primarily basal lobar pneumonia. Right lung:
perihilar inﬁltration. Intubation tube, central line, and gastric tube in loco typico.
Figure 3. Patient 6 at 4 months after admission. Coronal CT of the torso. Small
arrows: epiphrenic residual lesions. Small black arrows: hilar lymph nodes. CT
= computed tomography.
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of fever. Diagnostic imaging showed signs of pyomyositis and
fasciitis (Fig. 5). Purulent infections in the left anterior femoral
and anterior tibial compartments were surgically drained. The
previously healthy patient 8 presented with recurrent fever and
painful swelling of the upper arm, which had developed in 2
weeks. Prompt surgical intervention showed a purulent infection
of the ﬂexor compartment of the arm. Both patients were
discharged in satisfying general health.Figure 4. Patient 5 at 4 weeks after admission. Coronal MRI with TIRM
sequence of the torso. Large arrow: axillary abscess formation. Small arrows:
cellulitis. MRI =magnetic resonance imaging; TIRM= turbo-inversion recovery-
magnitude.
Figure 5. Patient 1 at 3 days after admission. Coronal contrast-enhanced MRI
with TIRM sequence of the lower extremities. Indicative of myositis and fasciitis.
Large arrow: feathered intramuscular enhancement. Small arrows: subcuta-
neous enhancement. Small black arrows: fascial enhancement. MRI =
magnetic resonance imaging; TIRM= turbo-inversion recovery-magnitude.
43.3. Others
Patient 7 and all family members initially presented with recurring
SSTI in our pediatric immunological clinic. PVL-MRSA was
detected in nasopharyngeal swabs and decolonization measures
were initiated. Four months later, he was re-admitted with
mastoiditis and cerebellitis (Fig. 6).Mastoidectomywasperformed
promptly and intravenous antibiotic treatment was initiated.
Patient 9 underwent heart transplantation at the age of one and a
half years. At the age of 8, she developed multiple and recurrent
abscesses over a period of 1 month while under immunosuppres-
sive therapy. After admission to the pediatric IMC, PVL-SA
detection, and 6 days of intravenous antibiotic treatment plus
hygienic measures to decolonize the patient and her home, the
patient was discharged in satisfying general health.Oneweek after
her birth, patient 10 developed massive swelling of the eyelid and
purulent secretion with detection of S aureus. PVL testing was
performed when the patient developed SSTI after discharge from
hospital.[17]
Figure 6. Patient 7 at admission. Coronal contrast-enhanced T1-weighted
MRI of the head with fat suppression. Large arrow: abscess-forming,
destructive mastoiditis with inﬁltration into the cerebellum. Small arrows:
meningeal enhancement. Small black arrows: cervical lymphadenopathy. MRI
= magnetic resonance imaging.
Figure 8. Patient 7 at admission. Coronal contrast-enhanced T1-weighted
cranial MRI with fat suppression. Large arrow: thrombosis of sigmoid sinus.
Small arrows: meningeal enhancement. MRI = magnetic resonance imaging.
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Two patients presented with deep venous thrombosis (DVT)
associated with PVL-SA infection of the adjacent tissue. Patient 1
(see above) initially presented with extensive thrombosis of the
left communal femoral vein. Despite prompt initiation of
therapeutic anticoagulation, the size of the thrombosis initially
increased further (Fig. 7). A cranial magnetic resonance imaging
of patient 7 (Fig. 8) revealed a thrombosis of the left sigmoid
venous sinus and the distal jugular vein, as complication of a
mastoiditis and SSTI of the neck. Both patients were treated with
low molecular weight heparin, for which high doses were
required to reach a therapeutic anti Xa level of 0.5 to 1IU/mL.Figure 7. Patient 1 at 3 days after admission. Axial contrast-enhanced T1-
weighted MRI with fat suppression of the proximal left lower thigh. Large arrow:
abscess formation with circular contrast enhancement in the ventral
compartment. Small arrows: thrombosis of deep veins. Small black arrows:
subcutaneous veins with contrast. MRI = magnetic resonance imaging.
53.5. Preventability
As presented in Figure 9, only in 4 out of 10 patients, history of
patients or of household members was not suggestive of PVL-SA
colonization before admission, due to severe infections. Three
patients had recently suffered from SSTI, 2 from recurrent
furunculosis (plus panaritia in 1 patient) and 1 from a single
axillary abscess. In 2 patients recurrent SSTI was reported in
relatives (in the parents in 1 patient and in a grandparent in
another patient), who had not been tested for PVL-SA. The PVL-
MRSA colonization of patient 7 and his family was known before
he acquired severe mastoiditis. He and his family had been given
instructions for decolonization (comprising 5 days of mupirocin
nose ointment, throat rinses, antiseptic washings, and change of









No history of SSTI
Figure 9. History of SSTI in patients and relatives of our cohort before
admission for serious infection (n=10). SSTI = skin and soft tissue infections.
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The present study outlines the clinical spectrum of severe PVL-SA
infections in children. Ten out of 75 children treated for PVL-SA
infections at our center developed an infection classiﬁed as severe,
within 5 years.
The clinical phenotypes described in our study correspondwith
results from other clinical and epidemiological studies, particu-
larly regarding the phenotypes of formerly healthy affected
children and the presence of URTI symptoms before admission
for pneumonia.[18] DVT is increasingly being detected in patients
with infections caused by PVL-SA.[19] In our cohort, 2 out of 10
patients developed symptomatic DVT. In both patients reported
in this study, DVT was associated with extensive SSTI of the
tissue surrounding the involved vessels.
It remains unclear whether it is the higher virulence of PVL-SA
in general or if pathogen speciﬁc mechanisms contribute to
thrombus formation in these patients. In an ex vivo model, it was
shown that PVL activates platelets via neutrophil secretion
products in patients with S aureus positive osteomyelitis,[20]
potentially contributing to thrombus formation. In a mouse
model, early antibiotic treatment signiﬁcantly reduced cytokine
synthesis, thrombin generation, and thrombo-inﬂammatory
response in MRSA infection. These results support our
observation that infection control is crucial for thrombus
control.[21]
Patient 1 in our study presented with an extensive venous
thrombosis of the lower extremity. Although anticoagulation
treatment was administrated immediately, the clinical situation
worsened. Concomitant symptoms such as fever, pneumonia,
and swelling of the surrounding tissue were at ﬁrst misinterpreted
as secondary to venous thromboembolism, leading to delay in
causal treatment for staphylococcal infection. Severe PVL-SA
associated infections are still rare in children. A high index of
suspicion for the association of DVT and PVL-SA infections is
warranted for prompt diagnosis and treatment. This approach
may improve outcomes and minimize morbidity.
Thrombotic complications in children are rare. However, the
serious thrombotic complications observed in our patients and in
previous studies[22] mandate the need for investigating whether
thromboprophylaxis, for instance, with low molecular heparin,
should be routinely administered in children with severe PVL-SA
infection. Further studies are required to identify the appropriate
recipients of prophylactic anticoagulation in this high-risk patient
group.
In 6 out of the 10 presented cases, either the patients themselves
or their close contacts experienced symptoms suggestive of PVL-
SA infection before admission due to serious infections. Prompt
testing for PVL colonization in affected individuals, followed by
subsequent decolonization procedures as suggested by Shallcross
et al[6] may have prevented severe disease in these patients.
However, in 1 case (patient 7), prior decolonization measures
(mupirocin nasal ointment, antiseptic throat rinses, antiseptic
washings, change of towels, bed linen and clothes, and
disinfection of potentially contaminated items over a period of
5 days [6]) had been initiated but had not been successful.
Subsequently, an acute life-threatening illness occurred that
might have been preventable by control swabs and a second
decolonization procedure. Recommended decolonization mea-
sures for PVL-SA are frequently difﬁcult to implement. Patients
and physicians report low adherence, because the measures are
time-consuming and costly, particularly in multi-person house-6holds. Further study to improve the rate of persistent decoloni-
zation and the practicability of the decolonization measures is
needed.
In our study, only 1 child was immunocompromised. She
developed multiple recurring deep furuncles and abscesses, rather
than 1 life-threatening infection. In contrast, the 2 teenagers with
necrotizing pneumonia had been healthy boys and were active in
youth athletics. Both fell ill with life-threatening infections
without any warning signs. A recent outbreak analysis of PVL-SA
in a German kindergarten showed that even in a close social
group, with the same strain of PVL-SA, not all colonized children
showed symptoms.[4] It has yet to be determined, which PVL-SA
colonized patients(1) remain asymptomatic,
(2) suffer from recurrent minor SSTI or
(3) develop severe infections.
A recent study by Tromp et al investigated the molecular
tropism of the leucocidin to human phagocytes and identiﬁed
human surface antigen CD45 to be a binding molecule for the
PVL-component LukF.[23] Determination of whether speciﬁc
binding properties of PVL mediate different clinical phenotypes
or speciﬁc host factors are of importance warrants further
studies.
The limitations of this study are the small number of patients
and the retrospective study design. Furthermore, we were unable
to evaluate preventive measures.
In conclusion, increased awareness of PVL-SA-associated
disease, together with routine diagnostic testing and knowledge
of potential complications and adequate therapeutic strategies
are important(1) to prevent severe infections by early diagnosis and consequent
decolonization and(2) to prevent serious complications such as DVT.
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